Pay in 4 interest-free payments of $25.00 Learn more
Ships within 48 hours · Estimated delivery Aug 4 - Aug 9
ERRgamma could be a novel therapeutic target for prostate cancer treatment
BMS-906024 enhances Paclitaxel-mediated cytotoxicity in vivo in NSCLC through a combination of inhibiting proliferation and promoting apoptosis
coli bacteria
COC(=O)CCP(CCC(=O)OC)C1C=CC=CC=1
SAH-SOS1A dehydroandrographolide ERRgamma could be a novelSAH SOS1A is a peptide based SOS1 KRAS protein interaction inhibitor. SAH SOS1A binds to wild type and mutant KRAS (G12D, G12V, G12C, G12S, and Q61H) with nanomolar affinity (EC50=106 175 nM), directly and independently blocks nucleotide association, impairs KRAS driven cancer cell viability, and exerts its effects by on mechanism blockade of the ERK MAPK phosphosignaling cascade downstream of KRAS. Product information CAS Number: 1652561 87 9
US$ 119.50
US$ 139.00
US$ 143.00
US$ 74.00
US$ 114.99
US$ 63.00
US$ 160.00
US$ 150.00
US$ 29.99